A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

Exclusion Criteria

• •Evidence of infection with hepatitis A, C, D or E virus infection or evidence of human immunodeficiency, virus type 1 (HIV-1) or HIV-2 infection at screening
• •History or evidence of clinical signs/symptoms of hepatic decompensation including but not limited to: portal hypertension, ascites, hepatic encephalopathy, esophageal varices or any laboratory abnormalities indicating a reduced liver function as defined in the protocol
• •Evidence of liver disease of non-HBV etiology
• •Signs of hepatocellular carcinoma (HCC)
• •Significant laboratory abnormalities as defined in the protocol at screening
• •Participants with a history of malignancy within 5 years before screening
• •Abnormal sinus rhythm or ECG parameters at screening as defined in the protocol
• •History of or current cardiac arrhythmia or history or clinical evidence of significant or unstable cardiac disease
• •Participants with any current or previous illness for which, in the opinion of the investigator and/or sponsor, participation would not be in the best interest of the participant
• •History of or current clinically significant skin disease or drug rash
• •Participants with known allergies, hypersensitivity, or intolerance to JNJ-3989 and JNJ 6379 or their excipients or excipients of the placebo content
• •Contraindications to the use of entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF) per local prescribing information
• •Participants who have taken any therapies disallowed per protocol
• •Female participants who are pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 90 days after the last dose of study intervention
• •Male participants who plan to father a child while enrolled
• •Participants who had or planned major surgery, (example, requiring general anesthesia) or who have received an organ transplant
• •Vulnerable participants (example, incarcerated individuals, individuals under a legal protection measure)